BLA 761060 · Wyeth Pharms INC
Mylotarg
Gemtuzumab Ozogamicin · Single-Dose · CD33-directed Immunoconjugate
OrphanLast checked: Nov 20, 2026Latest source record: Jun 16, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Sep 1, 2017
Approved uses
3
Original approval plus efficacy supplements
Registered trials
105
26 Phase 3, 17 recruiting
FAERS reports
3,665
3,554 serious, 1,135 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: HEPATOTOXICITY Hepatotoxicity, including severe or fatal hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), has been reported in association with the use of MYLOTARG as a single agent, and as part of a combination chemotherapy regimen. Monitor frequently for signs and symptoms of VOD after treatment with MYLOTARG. ( 5.1 and 6.1 ) WARNING: HEPATOTOXICITY See full prescribing information for complete boxed warning. Hepatotoxicity, including severe or fatal hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), has been reported in association with the use of MYLOTARG. ( 5.1 , 6.1 )
What it is approved for
From the label in effect Dec 19, 2025.
MYLOTARG is a CD33-directed antibody and cytotoxic drug conjugate indicated for: • treatment of newly-diagnosed CD33-positive acute myeloid leukemia (AML) in adults and pediatric patients 1 month and older ( 1.1 ). • treatment of relapsed or refractory CD33-positive AML in adults and pediatric patients 2 years and older ( 1.2 ). 1.1 Newly-Diagnosed CD33-positive Acute Myeloid Leukemia (AML) MYLOTARG is indicated for the treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and pediatric patients 1 month and older. 1.2 Relapsed or Refractory CD33-positive AML MYLOTARG is indicated for the treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and pediatric patients 2 years and older.
Mechanism: Gemtuzumab ozogamicin is a CD33-directed antibody-drug conjugate (ADC). The antibody portion (hP67.6) recognizes human CD33 antigen. The small molecule, N-acetyl gamma calicheamicin, is a cytotoxic agent that is covalently attached to the antibody via a linker. Nonclinical data suggest that the anticancer activity of gemtuzumab ozogamicin is due to the binding of the ADC to CD33-expressing tumor cells, followed by internalization of the ADC-CD33 complex, and the intracellular release of N-acetyl gamma calicheamicin dimethyl hydrazide via hydrolytic cleavage of the linker. Activation of...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 16, 2020 Supplement 4 · Efficacy · priority review OrphanLabelLetter
- Sep 1, 2017 Original approval · Type 4 - New Combination OrphanLabelLetterReview
- Sep 1, 2017 Original approval · Efficacy OrphanLetterReview
1 products under this application
- MYLOTARG · GEMTUZUMAB OZOGAMICIN 4.5MG · VIAL, SINGLE-DOSE · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Gemtuzumab Ozogamicin" as an intervention, any sponsor and status, largest first.
National Cancer Institute (NCI)NIH
NCT05564390 · 2,000 participants (planned) · Start Jun 18, 2024 · Primary completion May 15, 2029
Drug: Azacitidine; Azacitidine and 18 more · For: Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm; Acute Myeloid Leukemia Post Cytotoxic Therapy and 2 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 360 sites in all
- Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromesPivotal-lookingCompleted
The University of New South WalesAcademic, hospital or other
NCT00454480 · 2,000 participants (planned) · Start Aug 2006 · Primary completion Aug 2012
Drug: alemtuzumab; arsenic trioxide and 9 more · For: Leukemia; Myelodysplastic Syndromes
Sites: Basingstoke, United Kingdom; Bath, United Kingdom; Birmingham, United Kingdom · 96 sites in all
- Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy CombinationsPivotal-lookingStatus unknown
Cardiff UniversityAcademic, hospital or other
NCT02272478 · 1,600 participants (planned) · Start Oct 30, 2014 · Primary completion Feb 2021
Drug: Arm A Mylotarg plus DA Versus CPX-351; Arm B Vosaroxin and Decitabine and 4 more · For: Acute Myeloid Leukaemia; Myelodysplastic Syndrome
Sites: Aalborg, Denmark; Aarhus, Denmark; Copenhagen, Denmark · 87 sites in all
- A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 MutationsPivotal-lookingRecruiting
Children's Oncology GroupResearch network
NCT04293562 · 1,400 participants (planned) · Start Jul 21, 2020 · Primary completion Jun 30, 2029
Drug: Asparaginase Erwinia chrysanthemi; Cytarabine and 9 more · For: Acute Myeloid Leukemia
Sites: Birmingham, Alabama; Mobile, Alabama; Mesa, Arizona · 206 sites in all
- Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid LeukemiaPivotal-lookingCompleted
Children's Oncology GroupResearch network
NCT00372593 · 1,070 participants · Start Aug 2006 · Primary completion Aug 2013
Drug: asparaginase; cytarabine and 4 more · For: Leukemia
Sites: Birmingham, Alabama; Mobile, Alabama; Mesa, Arizona · 198 sites in all
- CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML PatientsPivotal-lookingRecruiting
Princess Maxima Center for Pediatric OncologyAcademic, hospital or other
NCT05994690 · 905 participants (planned) · Start Jul 14, 2023 · Primary completion Mar 2031
Drug: Standard Intervention Rc; Investigational Intervention Rc and 2 more · For: Acute Myeloid Leukemia in Children
Sites: Utrecht, Netherlands
- International Randomised Phase III Clinical Trial in Children With Acute Myeloid LeukaemiaPivotal-lookingActive, not recruiting
University of BirminghamAcademic, hospital or other
NCT02724163 · 700 participants (planned) · Start Apr 2016 · Primary completion Dec 2031
Drug: Gemtuzumab ozogamicin; Liposomal daunorubicin and 5 more · For: Acute Myeloid Leukaemia
Sites: Adelaide, Australia; Brisbane, Australia; Melbourne, Australia · 68 sites in all
- Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML LeukemiaPivotal-lookingCompleted
Eastern Cooperative Oncology GroupResearch network
NCT00049517 · 657 participants · Start Dec 19, 2002 · Primary completion Mar 2009
Drug: sargramostim; busulfan and 4 more · For: Leukemia
Sites: Birmingham, Alabama; Scottsdale, Arizona; Aurora, Colorado · 99 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- febrile neutropenia698
- pyrexia326
- sepsis302
- venoocclusive liver disease260
- thrombocytopenia240
- platelet count decreased236
- pneumonia197
- neutropenia194
- white blood cell count decreased185
- aspartate aminotransferase increased184
- off label use174
- alanine aminotransferase increased163
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 127 |
| 2005 | 156 |
| 2006 | 311 |
| 2007 | 192 |
| 2008 | 118 |
| 2009 | 135 |
| 2010 | 135 |
| 2011 | 200 |
| 2012 | 101 |
| 2013 | 64 |
| 2014 | 52 |
| 2015 | 83 |
| 2016 | 77 |
| 2017 | 122 |
| 2018 | 221 |
| 2019 | 177 |
| 2020 | 259 |
| 2021 | 315 |
| 2022 | 242 |
| 2023 | 220 |
| 2024 | 149 |
| 2025 | 129 |
| 2026 | 77 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Mylotarg (Gemtuzumab Ozogamicin) · HCPCS J9203
2024 spending
$2.4M
Beneficiaries
91
194 claims
Per beneficiary
$26,779
2024 ASP limit $227.98 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $3,602,963 |
| 2021 | $2,808,760 |
| 2022 | $3,169,326 |
| 2023 | $2,267,759 |
| 2024 | $2,436,886 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial.
Lambert J, Pautas C, Terré C, et al. · Haematologica 2019 · Clinical Trial, Phase III, Multicenter Study
- Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.
Hills RK, Castaigne S, Appelbaum FR, et al. · Lancet Oncol 2014 · Meta-Analysis, Review
- Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.
Castaigne S, Pautas C, Terré C, et al. · Lancet 2012 · Clinical Trial, Phase III, Multicenter Study
- Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Burnett AK, Russell NH, Hills RK, et al. · Lancet Oncol 2015 · Clinical Trial, Phase III, Comparative Study
- Efficacy and safety of adding gemtuzumab ozogamicin to conventional chemotherapy for adult acute myeloid leukemia: a systematic review and meta-analysis.
Guo Y, Deng L, Qiao Y, et al. · Hematology 2022 · Meta-Analysis, Systematic Review
- A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia.
Short NJ, Borthakur G, Pemmaraju N, et al. · Leuk Lymphoma 2022 · Clinical Trial, Phase I, Clinical Trial, Phase II
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.